UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 気管支肺異形成症の病因および臨床的特徴 pathogenesis and clinical features of bronchopulmonary dysplasia
2. 胃酸分泌の生理学 physiology of gastric acid secretion
3. ヘリコバクターピロリ感染と十二指腸潰瘍の関連性 association between helicobacter pylori infection and duodenal ulcer
4. 気管支神経内分泌（カルチノイド）腫瘍：疫学、危険因子、分類、組織学的検査、診断、および病期分類 bronchial neuroendocrine carcinoid tumors epidemiology risk factors classification histology diagnosis and staging
5. 小細胞肺癌の病理および病期分類 pathobiology and staging of small cell carcinoma of the lung

English Journal

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Inomata M1, Hayashi R1, Yamamoto A1, Tokui K1, Taka C1, Okazawa S1, Kambara K1, Suzuki K2, Ichikawa T1, Yamada T1, Miwa T1, Kashii T3, Matsui S4, Tobe K1, Imura J5.
Molecular and clinical oncology.Mol Clin Oncol.2015 Jul;3(4):802-806. Epub 2015 May 14.
Determination of the presence of epidermal growth factor receptor (EGFR) gene mutation is useful for predicting the efficacy of gefitinib. However, the survival rate following the initiation of treatment with gefitinib varies among individuals. A retrospective study was conducted to investigate the
PMID 26171184

Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy.

Ischia J1, Patel O, Sethi K, Nordlund MS, Bolton D, Shulkes A, Baldwin GS.
BJU international.BJU Int.2015 May;115(5):829-38. doi: 10.1111/bju.12886. Epub 2015 Jan 26.
OBJECTIVE: To determine the expression and biology of the neuroendocrine growth factor gastrin-releasing peptide (GRP) and other proGRP-derived peptides in renal cancer.MATERIALS AND METHODS: Receptor binding studies, enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay, were used to quant
PMID 25130393

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.

Korse CM1, Holdenrieder S2, Zhi XY3, Zhang X4, Qiu L5, Geistanger A6, Lisy MR7, Wehnl B8, van den Broek D9, Escudero JM10, Standop J11, Hu M12, Molina R13.
Clinica chimica acta; international journal of clinical chemistry.Clin Chim Acta.2015 Jan 1;438:388-95. doi: 10.1016/j.cca.2014.09.015. Epub 2014 Sep 28.
BACKGROUND: We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China.METHODS: The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer.
PMID 25262909